The LPAR1 antagonist, PIPE-791 produces antifibrotic effects in models of lung fibrosis
We show that PIPE-791 effectively reduces fibrosis and fibrotic markers in vitro and in vivo and that it has slow association and dissociation kinetics. Taken together, our data support clinical testing of PIPE-791 in the context of fibrotic conditions such as IPF.
Authors
- Didier Bagnol
- Christopher Baccei
- Jeffrey Roppe
- Thomas O. Schrader (ORCID: https://orcid.org/0000-0003-3468-9566)
- Michael M. Poon (ORCID: https://orcid.org/0009-0001-2978-5855)
- Karin J. Stebbins
- Yifeng Xiong (ORCID: https://orcid.org/0000-0002-6727-6373)
- Alexander Broadhead
- Gregory Joseph (ORCID: https://orcid.org/0000-0002-0250-761X)
- Lino J. Valdez
- Kym I. Lorrain
- Geraldine C. Edu
- Daniel S. Lorrain
Institutions
- General Atomics (United States) (US)
Publication Details
- Journal
- Respiratory Research
- Published
- 2025-08-31
- DOI
- https://doi.org/10.1186/s12931-025-03340-4
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00